Add-on treatment with pyridoxine and sulthiame in 12 infants with West syndrome: an open clinical study.
To investigate the effect of sulthiame (STM) in West syndrome (WS) an open, uncontrolled add-on study was undertaken during initial pyridoxine (PDX) therapy in 12 infants, two with idiopathic and ten with symptomatic WS. All patients were initially treated with PDX (150-300 mg x kg (-1)body weight day(-1) ). In seven patients (58%) seizures and hypsarrhythmia stopped during the week after introduction of STM (10 mg x kg (-1)body weight day (-1)). In one the positive effect was temporary. Five of the responders (42%) remained seizure-free and without hypsarrhythmia under STM monotherapy, while one developed complex partial seizures after 25 months. STM was most effective in idiopathic WS (2 /2). During treatment with STM medication no patient suffered side effects attributable to the substance. Further controlled studies are necessary to evaluate the benefit of this potentially effective treatment.
Debus
Otfried Martin
OM
University Children's Hospital, Department of Neuropediatrics, Westfälische-Wilhelms-Universität Münster, Albert-Schweitzer-Str. 33, D - 48149 Münster, Germany. debuso@uni-muenster.de
Köhring
Jessika
J
Fiedler
Barbara
B
Franssen
Maike
M
Kurlemann
Gerhard
G
D000927:Anticonvulsants / Q000627:therapeutic use*; D002220:Carbamazepine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D006801:Humans; D007223:Infant; D008297:Male; D011736:Pyridoxine / Q000627:therapeutic use*; D013036:Spasms, Infantile / Q000188:drug therapy*; D013843:Thiazines / Q000627:therapeutic use*; D000096926:Benzenesulfonamides
D000927:Anticonvulsants; D002220:Carbamazepine; D011736:Pyridoxine; D013843:Thiazines; C084593:sulthiame; D000096926:Benzenesulfonamides